Does the media prefer LMAT or NPCE?

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 1 articles in the media. LeMaitre Vascular's average media sentiment score of 1.53 beat NeuroPace's score of 1.47 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INSP or NPCE?

In the previous week, Inspire Medical Systems had 8 more articles in the media than NeuroPace. MarketBeat recorded 9 mentions for Inspire Medical Systems and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.47 beat Inspire Medical Systems' score of 1.32 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NPCE or OMCL?

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 4.78 -$21.47M -$0.57 N/A Omnicell $1.18B 1.25 $2.05M $0.84 38.73

Is NPCE or OMCL more profitable?

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -19.34%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -19.34% -105.64% -16.51% Omnicell 3.13% 5.66% 3.57%

Does the media prefer NPCE or OMCL?

In the previous week, Omnicell had 5 more articles in the media than NeuroPace. MarketBeat recorded 6 mentions for Omnicell and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.47 beat Omnicell's score of 1.23 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NPCE or TNDM?

In the previous week, Tandem Diabetes Care had 1 more articles in the media than NeuroPace. MarketBeat recorded 2 mentions for Tandem Diabetes Care and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.47 beat Tandem Diabetes Care's score of 1.15 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tandem Diabetes Care 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NPCE or KMTS?

In the previous week, Kestra Medical Technologies had 4 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for Kestra Medical Technologies and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.47 beat Kestra Medical Technologies' score of 0.16 indicating that NeuroPace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kestra Medical Technologies 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NeuroPace (NPCE) Competitors

$13.91 -0.59 (-4.04%)

As of 01:13 PM Eastern

Compare

NPCE vs. LMAT, INSP, OMCL, TNDM, and KMTS

Should you buy NeuroPace stock or one of its competitors? NeuroPace's main competitors and comparable companies include LeMaitre Vascular (LMAT), Inspire Medical Systems (INSP), Omnicell (OMCL), Tandem Diabetes Care (TNDM), and Kestra Medical Technologies (KMTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeuroPace compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

LeMaitre Vascular has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market.

LeMaitre Vascular has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	7.33	$57.73M	$2.85	28.08
NeuroPace	$99.99M	4.78	-$21.47M	-$0.57	N/A

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 1 articles in the media. LeMaitre Vascular's average media sentiment score of 1.53 beat NeuroPace's score of 1.47 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular presently has a consensus target price of $110.60, suggesting a potential upside of 38.18%. NeuroPace has a consensus target price of $19.29, suggesting a potential upside of 38.61%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

LeMaitre Vascular has a net margin of 25.02% compared to NeuroPace's net margin of -19.34%. LeMaitre Vascular's return on equity of 15.63% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	25.02%	15.63%	10.06%
NeuroPace	-19.34%	-105.64%	-16.51%

Summary

LeMaitre Vascular beats NeuroPace on 10 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Inspire Medical Systems has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market.

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 2.2% of Inspire Medical Systems shares are held by insiders. Comparatively, 19.2% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Inspire Medical Systems has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	2.13	$145.42M	$4.62	14.55
NeuroPace	$99.99M	4.78	-$21.47M	-$0.57	N/A

In the previous week, Inspire Medical Systems had 8 more articles in the media than NeuroPace. MarketBeat recorded 9 mentions for Inspire Medical Systems and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.47 beat Inspire Medical Systems' score of 1.32 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inspire Medical Systems has a net margin of 15.03% compared to NeuroPace's net margin of -19.34%. Inspire Medical Systems' return on equity of 8.64% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
NeuroPace	-19.34%	-105.64%	-16.51%

Inspire Medical Systems presently has a consensus target price of $66.19, indicating a potential downside of 1.57%. NeuroPace has a consensus target price of $19.29, indicating a potential upside of 38.61%. Given NeuroPace's stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Inspire Medical Systems beats NeuroPace on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Omnicell?

NeuroPace (NASDAQ:NPCE) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

NeuroPace has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

In the previous week, Omnicell had 5 more articles in the media than NeuroPace. MarketBeat recorded 6 mentions for Omnicell and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.47 beat Omnicell's score of 1.23 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.78	-$21.47M	-$0.57	N/A
Omnicell	$1.18B	1.25	$2.05M	$0.84	38.73

NeuroPace presently has a consensus price target of $19.29, suggesting a potential upside of 38.61%. Omnicell has a consensus price target of $57.86, suggesting a potential upside of 77.86%. Given Omnicell's higher probable upside, analysts plainly believe Omnicell is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 19.2% of NeuroPace shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Omnicell has a net margin of 3.13% compared to NeuroPace's net margin of -19.34%. Omnicell's return on equity of 5.66% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Omnicell	3.13%	5.66%	3.57%

Summary

Omnicell beats NeuroPace on 11 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Tandem Diabetes Care?

NeuroPace (NASDAQ:NPCE) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Tandem Diabetes Care has a net margin of -6.08% compared to NeuroPace's net margin of -19.34%. Tandem Diabetes Care's return on equity of -45.97% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

In the previous week, Tandem Diabetes Care had 1 more articles in the media than NeuroPace. MarketBeat recorded 2 mentions for Tandem Diabetes Care and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.47 beat Tandem Diabetes Care's score of 1.15 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of NeuroPace shares are held by institutional investors. 19.2% of NeuroPace shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeuroPace has higher earnings, but lower revenue than Tandem Diabetes Care. NeuroPace is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.78	-$21.47M	-$0.57	N/A
Tandem Diabetes Care	$1.01B	1.26	-$204.71M	-$0.93	N/A

NeuroPace has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

NeuroPace currently has a consensus price target of $19.29, suggesting a potential upside of 38.61%. Tandem Diabetes Care has a consensus price target of $29.34, suggesting a potential upside of 59.60%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

Summary

NeuroPace and Tandem Diabetes Care tied by winning 8 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Kestra Medical Technologies?

NeuroPace (NASDAQ:NPCE) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

NeuroPace has higher revenue and earnings than Kestra Medical Technologies. NeuroPace is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	4.78	-$21.47M	-$0.57	N/A
Kestra Medical Technologies	$95.13M	14.73	-$131.61M	-$2.42	N/A

In the previous week, Kestra Medical Technologies had 4 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for Kestra Medical Technologies and 1 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.47 beat Kestra Medical Technologies' score of 0.16 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kestra Medical Technologies	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroPace currently has a consensus price target of $19.29, suggesting a potential upside of 38.61%. Kestra Medical Technologies has a consensus price target of $28.14, suggesting a potential upside of 17.65%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

NeuroPace has a net margin of -19.34% compared to Kestra Medical Technologies' net margin of -138.35%. Kestra Medical Technologies' return on equity of -57.38% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Kestra Medical Technologies	-138.35%	-57.38%	-41.10%

78.8% of NeuroPace shares are owned by institutional investors. 19.2% of NeuroPace shares are owned by insiders. Comparatively, 5.3% of Kestra Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeuroPace has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Summary

NeuroPace beats Kestra Medical Technologies on 13 of the 17 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$479.45M	$5.42B	$7.12B	$12.73B
Dividend Yield	N/A	1.78%	2.55%	9.16%
P/E Ratio	-24.51	24.78	273.64	25.24
Price / Sales	4.78	74.74	670.66	117.33
Price / Cash	N/A	32.78	77.55	52.32
Price / Book	24.41	5.91	10.45	6.21
Net Income	-$21.47M	$150.94M	$3.49B	$358.07M
7 Day Performance	-5.67%	-2.64%	-2.65%	-2.03%
1 Month Performance	-6.49%	-2.90%	0.39%	-2.19%
1 Year Performance	43.89%	8.58%	20.70%	10.26%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	3.6535 of 5 stars	$13.91 -4.0%	$19.29 +38.6%	+45.4%	$479.45M	$99.99M	N/A	170	Positive News
LMAT LeMaitre Vascular	4.7537 of 5 stars	$80.81 +0.7%	$110.60 +36.9%	-16.9%	$1.85B	$249.60M	28.35	490	Positive News
INSP Inspire Medical Systems	2.5977 of 5 stars	$61.67 -2.1%	$66.19 +7.3%	-18.4%	$1.78B	$911.98M	13.35	1,333	Positive News Gap Down
OMCL Omnicell	4.2662 of 5 stars	$34.25 -2.6%	$57.86 +68.9%	+2.7%	$1.56B	$1.18B	40.77	3,580	Positive News Analyst Upgrade
TNDM Tandem Diabetes Care	3.4081 of 5 stars	$21.71 -1.4%	$28.98 +33.5%	+52.1%	$1.51B	$1.01B	N/A	2,500	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors

NPCE vs. LMAT, INSP, OMCL, TNDM, and KMTS

How does NeuroPace compare to LeMaitre Vascular?

Summary

How does NeuroPace compare to Inspire Medical Systems?

Summary

How does NeuroPace compare to Omnicell?

Summary

How does NeuroPace compare to Tandem Diabetes Care?

Summary

How does NeuroPace compare to Kestra Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroPace (NPCE) Competitors

NPCE vs. LMAT, INSP, OMCL, TNDM, and KMTS

How does NeuroPace compare to LeMaitre Vascular?

Which has more risk & volatility, LMAT or NPCE?

Which has stronger earnings and valuation, LMAT or NPCE?

Do insiders and institutionals hold more shares of LMAT or NPCE?

Does the media prefer LMAT or NPCE?

Do analysts prefer LMAT or NPCE?

Is LMAT or NPCE more profitable?

Summary

How does NeuroPace compare to Inspire Medical Systems?

Which has more risk and volatility, INSP or NPCE?

Do insiders and institutionals believe in INSP or NPCE?

Which has stronger valuation & earnings, INSP or NPCE?

Does the media refer more to INSP or NPCE?

Is INSP or NPCE more profitable?

Do analysts recommend INSP or NPCE?

Summary

How does NeuroPace compare to Omnicell?

Which has more volatility and risk, NPCE or OMCL?

Does the media prefer NPCE or OMCL?

Which has preferable earnings & valuation, NPCE or OMCL?

Do analysts prefer NPCE or OMCL?

Do institutionals & insiders hold more shares of NPCE or OMCL?

Is NPCE or OMCL more profitable?

Summary

How does NeuroPace compare to Tandem Diabetes Care?

Is NPCE or TNDM more profitable?

Does the media prefer NPCE or TNDM?

Do institutionals & insiders believe in NPCE or TNDM?

Which has stronger valuation and earnings, NPCE or TNDM?

Which has more volatility & risk, NPCE or TNDM?

Do analysts rate NPCE or TNDM?

Summary

How does NeuroPace compare to Kestra Medical Technologies?

Which has stronger earnings and valuation, NPCE or KMTS?

Does the media prefer NPCE or KMTS?

Do analysts rate NPCE or KMTS?

Is NPCE or KMTS more profitable?

Do institutionals and insiders hold more shares of NPCE or KMTS?

Which has more risk & volatility, NPCE or KMTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools